Safety outcomes from a phase IV pediatric registry: Etanercept (Enbrel (R)) therapy in children and adolescents with juvenile rheumatoid arthritis (JRA)
Publication
, Conference
Giannini, EH; Lovell, DJ; Ilowite, NT; Wallace, CA; Schanberg, LE
Published in: ARTHRITIS AND RHEUMATISM
September 1, 2004
Duke Scholars
Published In
ARTHRITIS AND RHEUMATISM
ISSN
0004-3591
Publication Date
September 1, 2004
Volume
50
Issue
9
Start / End Page
S90 / S91
Location
San Antonio, TX
Publisher
WILEY-LISS
Conference Name
68th Annual Scientific Meeting of the American-College-of-Rheumatology/39th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals
Related Subject Headings
- Arthritis & Rheumatology
- 1117 Public Health and Health Services
- 1107 Immunology
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Giannini, E. H., Lovell, D. J., Ilowite, N. T., Wallace, C. A., & Schanberg, L. E. (2004). Safety outcomes from a phase IV pediatric registry: Etanercept (Enbrel (R)) therapy in children and adolescents with juvenile rheumatoid arthritis (JRA). In ARTHRITIS AND RHEUMATISM (Vol. 50, pp. S90–S91). San Antonio, TX: WILEY-LISS.
Giannini, E. H., D. J. Lovell, N. T. Ilowite, C. A. Wallace, and L. E. Schanberg. “Safety outcomes from a phase IV pediatric registry: Etanercept (Enbrel (R)) therapy in children and adolescents with juvenile rheumatoid arthritis (JRA).” In ARTHRITIS AND RHEUMATISM, 50:S90–91. WILEY-LISS, 2004.
Giannini EH, Lovell DJ, Ilowite NT, Wallace CA, Schanberg LE. Safety outcomes from a phase IV pediatric registry: Etanercept (Enbrel (R)) therapy in children and adolescents with juvenile rheumatoid arthritis (JRA). In: ARTHRITIS AND RHEUMATISM. WILEY-LISS; 2004. p. S90–1.
Giannini, E. H., et al. “Safety outcomes from a phase IV pediatric registry: Etanercept (Enbrel (R)) therapy in children and adolescents with juvenile rheumatoid arthritis (JRA).” ARTHRITIS AND RHEUMATISM, vol. 50, no. 9, WILEY-LISS, 2004, pp. S90–91.
Giannini EH, Lovell DJ, Ilowite NT, Wallace CA, Schanberg LE. Safety outcomes from a phase IV pediatric registry: Etanercept (Enbrel (R)) therapy in children and adolescents with juvenile rheumatoid arthritis (JRA). ARTHRITIS AND RHEUMATISM. WILEY-LISS; 2004. p. S90–S91.
Published In
ARTHRITIS AND RHEUMATISM
ISSN
0004-3591
Publication Date
September 1, 2004
Volume
50
Issue
9
Start / End Page
S90 / S91
Location
San Antonio, TX
Publisher
WILEY-LISS
Conference Name
68th Annual Scientific Meeting of the American-College-of-Rheumatology/39th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals
Related Subject Headings
- Arthritis & Rheumatology
- 1117 Public Health and Health Services
- 1107 Immunology
- 1103 Clinical Sciences